Detalhe da pesquisa
1.
Health-related quality of life in patients with ß-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Eur J Haematol
; 111(1): 113-124, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37095595
2.
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Blood
; 139(4): 624-629, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758066
3.
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Blood
; 140(20): 2170-2174, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797468
4.
REMS pharmacy tasks: The adoption of an innovative electronic support system.
J Am Pharm Assoc (2003)
; 59(5): 704-709, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31153825
5.
Luspatercept for the treatment of anaemia in non-transfusion-dependent ß-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Lancet Haematol
; 9(10): e733-e744, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36007538
6.
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
J Clin Med
; 11(1)2021 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35011768
7.
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Leukemia
; 36(5): 1432-1435, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220402
8.
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
J Clin Oncol
; 27(11): 1850-6, 2009 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19255328
9.
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
J Clin Oncol
; 24(24): 3895-903, 2006 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16921040